Zhejiang Garden BiopharmaceuticalLtd Management
Management criteria checks 4/4
Zhejiang Garden BiopharmaceuticalLtd's CEO is Huanzheng Ma, appointed in Oct 2003, has a tenure of 21.17 years. directly owns 0.69% of the company’s shares, worth CN¥55.76M. The average tenure of the management team and the board of directors is 16.3 years and 3.8 years respectively.
Key information
Huanzheng Ma
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 21.2yrs |
| CEO ownership | 0.7% |
| Management average tenure | 16.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues
Oct 24
Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Sep 29Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Sep 08Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge
Jun 30Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?
May 31Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%
May 06Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 22CEO
Huanzheng Ma (59 yo)
21.2yrs
Tenure
CN¥1,011,900
Compensation
Mr. Huanzheng Ma serves as General Manager and Vice Chairman of Zhejiang Garden Biopharmaceutical Co.,Ltd.(Formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd.) since October 10, 2003.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | 21.2yrs | CN¥1.01m | 0.69% CN¥ 55.8m | |
| VP, Secretary to the Board & Director | no data | CN¥700.00k | 0.52% CN¥ 41.8m | |
| Deputy General Manager | 21.2yrs | CN¥370.00k | 0.071% CN¥ 5.8m | |
| Executive Deputy General Manager | 16.3yrs | CN¥780.90k | 0.24% CN¥ 19.5m | |
| CFO & Financial Director | 8.7yrs | CN¥573.20k | no data | |
| Deputy General Manager | 11.4yrs | CN¥716.90k | 0.093% CN¥ 7.5m |
16.3yrs
Average Tenure
54yo
Average Age
Experienced Management: 300401's management team is seasoned and experienced (16.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | 21.2yrs | CN¥1.01m | 0.69% CN¥ 55.8m | |
| VP, Secretary to the Board & Director | 16.6yrs | CN¥700.00k | 0.52% CN¥ 41.8m | |
| Director | 21.2yrs | no data | no data | |
| Chairman of the Board | 3.8yrs | CN¥1.10m | 0.45% CN¥ 36.5m | |
| Independent Director | 3.8yrs | CN¥100.00k | no data | |
| Independent Director | 3.8yrs | CN¥100.00k | no data | |
| Chairman of the Supervisory Board | 7.1yrs | no data | no data | |
| Independent Director | 3.8yrs | CN¥100.00k | no data | |
| Vice Chairman | 2.7yrs | CN¥1.04m | no data | |
| Director | 2.7yrs | CN¥964.40k | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.8yrs
Average Tenure
55.5yo
Average Age
Experienced Board: 300401's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 19:55 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Garden Biopharmaceutical Co.,Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhe Wang | Citic Securities Co., Ltd. |
| Wei Liu | Haitong International Research Limited |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |